These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 26791800

  • 21. Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
    Kitazaki T, Fukuda Y, Fukahori S, Oyanagi K, Soda H, Nakamura Y, Kohno S.
    Support Care Cancer; 2015 Jan; 23(1):185-90. PubMed ID: 25063271
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H.
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K, Fushida S, Kaji M, Takeda T, Yabushita K, Nezuka H, Kinami S, Kadoya N, Takai Y, Tsukioka Y, Ohyama S, Tsuji K, Tsukada T, Kinoshita J, Fujimura T, Ohta T.
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a single institute].
    Osawa H, Goto H, Myojo T.
    Gan To Kagaku Ryoho; 2013 May; 40(5):617-21. PubMed ID: 23863585
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.
    Uchida M, Nakamura T, Makihara Y, Suetsugu K, Ikesue H, Mori Y, Kato K, Shiratsuchi M, Hosohata K, Miyamoto T, Akashi K.
    Pharmazie; 2018 May 01; 73(5):304-308. PubMed ID: 29724299
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
    Rugo HS, Rossi G, Rizzi G, Aapro M.
    Breast; 2017 Jun 01; 33():76-82. PubMed ID: 28285236
    [Abstract] [Full Text] [Related]

  • 39. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI, Lee DE, Cho I, Yoon JH, Yoon SS, Lee HS, Oh JM.
    Ann Pharmacother; 2012 Dec 01; 46(12):1637-44. PubMed ID: 23170032
    [Abstract] [Full Text] [Related]

  • 40. The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
    Mitsuhashi A, Usui H, Nishikimi K, Yamamoto N, Hanawa S, Tate S, Watanabe-Nemoto M, Uno T, Shozu M.
    Am J Clin Oncol; 2017 Apr 01; 40(2):118-121. PubMed ID: 25144265
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.